A novel reaction of α-haloketone (α-bromo and α-chloro ketone) with irradiation under microwave gave the corresponding α-hydroxyketone and pyrazine derivative in good yields. In the case of α,α′-dibromo ketone, α-diketone was obtained. This reaction affords a new, clean and convenient synthetic method for α-hydroxyketone, α-diketone, α-chloro ketone and pyrazine derivative.
Diarylpyrazine-based position isomers: A detailed study of optical properties and structure-property relationship
作者:Dong-Jin Park、Puttavva Meti、Young-Dae Gong
DOI:10.1016/j.dyepig.2020.108254
日期:2020.5
A versatile and expeditious synthetic route to pyrazine-based symmetric and asymmetricchromophores decorated with donor-acceptor (D-A) has been designed to study their structural effects on optical properties. Suzuki-Miyaura coupling of dihalopyrazine with various aryl boronic acids was synthesized under microwave condition. Pyrazine functionalized at C-2, C-5 and C-6 serve as acceptor to construct
Highly efficient synthesis of 2,5-disubstituted pyrazines from (Z)-β-haloenol acetates
作者:Zhengwang Chen、Dongnai Ye、Guohai Xu、Min Ye、Liangxian Liu
DOI:10.1039/c3ob41164h
日期:——
A highly efficient synthesis of a wide range of 2,5-disubstituted pyrazines from (Z)-β-haloenol acetates is described. The reactions are conducted under convenient conditions and provide products with excellent regioselectivity in moderate to excellent yields with a broad substrate scope, including a variety of aromatic and aliphatic haloenol acetates.
Pharmaceutical compositions for enhancing the expression of apoAI are provided, which are used as medicaments for treatment of cardiovascular diseases on the basis of improving the functions of HDL.
Pharmaceutical compositions for enhancing the expression of apoAI which comprises a compound of formula (I):
in which X
1
and X
1
are independently an aryl or heteroaryl that may be optionally substituted, a hydrogen, a halogen, or the like; ring A is a benzene ring or 6-membered aromatic heterocyclic ring containing 1 to 3 N atoms that may be optionally condensed with another aromatic ring; R
1
to R
4
are independently a hydrogen, a halogen, a lower alkyl, a lower alkoxy or the like; a prodrug thereof, a pharmaceutically acceptable salt or solvate of them are disclosed.